MX354127B - Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central. - Google Patents

Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central.

Info

Publication number
MX354127B
MX354127B MX2014011612A MX2014011612A MX354127B MX 354127 B MX354127 B MX 354127B MX 2014011612 A MX2014011612 A MX 2014011612A MX 2014011612 A MX2014011612 A MX 2014011612A MX 354127 B MX354127 B MX 354127B
Authority
MX
Mexico
Prior art keywords
nervous system
central nervous
tesaurismosis
lisosomic
treat
Prior art date
Application number
MX2014011612A
Other languages
English (en)
Other versions
MX2014011612A (es
Inventor
Boyd Robert
J Rybczynski Philip
Sheth Kamlesh
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2014011612A publication Critical patent/MX2014011612A/es
Publication of MX354127B publication Critical patent/MX354127B/es

Links

Classifications

    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10B—ELECTRONIC MEMORY DEVICES
    • H10B12/00—Dynamic random access memory [DRAM] devices
    • H10B12/01—Manufacture or treatment
    • H10B12/02—Manufacture or treatment for one transistor one-capacitor [1T-1C] memory cells
    • H10B12/03—Making the capacitor or connections thereto
    • H10B12/033—Making the capacitor or connections thereto the capacitor extending over the transistor
    • H10B12/0335—Making a connection between the transistor and the capacitor, e.g. plug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10B—ELECTRONIC MEMORY DEVICES
    • H10B12/00—Dynamic random access memory [DRAM] devices
    • H10B12/01—Manufacture or treatment
    • H10B12/02—Manufacture or treatment for one transistor one-capacitor [1T-1C] memory cells
    • H10B12/03—Making the capacitor or connections thereto
    • H10B12/033—Making the capacitor or connections thereto the capacitor extending over the transistor
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10B—ELECTRONIC MEMORY DEVICES
    • H10B12/00—Dynamic random access memory [DRAM] devices
    • H10B12/01—Manufacture or treatment
    • H10B12/02—Manufacture or treatment for one transistor one-capacitor [1T-1C] memory cells
    • H10B12/05—Making the transistor
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10B—ELECTRONIC MEMORY DEVICES
    • H10B12/00—Dynamic random access memory [DRAM] devices
    • H10B12/01—Manufacture or treatment
    • H10B12/09—Manufacture or treatment with simultaneous manufacture of the peripheral circuit region and memory cells
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10B—ELECTRONIC MEMORY DEVICES
    • H10B12/00—Dynamic random access memory [DRAM] devices
    • H10B12/30—DRAM devices comprising one-transistor - one-capacitor [1T-1C] memory cells
    • H10B12/31—DRAM devices comprising one-transistor - one-capacitor [1T-1C] memory cells having a storage electrode stacked over the transistor
    • H10B12/315—DRAM devices comprising one-transistor - one-capacitor [1T-1C] memory cells having a storage electrode stacked over the transistor with the capacitor higher than a bit line
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10D—INORGANIC ELECTRIC SEMICONDUCTOR DEVICES
    • H10D1/00—Resistors, capacitors or inductors
    • H10D1/60—Capacitors
    • H10D1/68—Capacitors having no potential barriers
    • H10D1/692—Electrodes
    • H10D1/711—Electrodes having non-planar surfaces, e.g. formed by texturisation
    • H10D1/716—Electrodes having non-planar surfaces, e.g. formed by texturisation having vertical extensions
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10P—GENERIC PROCESSES OR APPARATUS FOR THE MANUFACTURE OR TREATMENT OF DEVICES COVERED BY CLASS H10
    • H10P50/00—Etching of wafers, substrates or parts of devices
    • H10P50/20—Dry etching; Plasma etching; Reactive-ion etching
    • H10P50/28—Dry etching; Plasma etching; Reactive-ion etching of insulating materials
    • H10P50/282—Dry etching; Plasma etching; Reactive-ion etching of insulating materials of inorganic materials
    • H10P50/283—Dry etching; Plasma etching; Reactive-ion etching of insulating materials of inorganic materials by chemical means
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10P—GENERIC PROCESSES OR APPARATUS FOR THE MANUFACTURE OR TREATMENT OF DEVICES COVERED BY CLASS H10
    • H10P50/00—Etching of wafers, substrates or parts of devices
    • H10P50/71—Etching of wafers, substrates or parts of devices using masks for conductive or resistive materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen sales novedosas del compuesto (3R,4R,5S)-5-(difluorom etil)piperidin-3,4-diol, así como también métodos que las utilizan para prevenir y/o tratar tesaurismosis lisosámicas y/o trastornos degenerativos del sistema nervioso central. En particular, la presente invención proporciona métodos para prevenir y/o tratar la enfermedad de Gaucher y/o la enfermedad de Parkinson.
MX2014011612A 2012-03-27 2013-03-07 Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central. MX354127B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261616159P 2012-03-27 2012-03-27
PCT/US2013/029612 WO2013148103A1 (en) 2012-03-27 2013-03-07 Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system

Publications (2)

Publication Number Publication Date
MX2014011612A MX2014011612A (es) 2014-10-17
MX354127B true MX354127B (es) 2018-02-14

Family

ID=47902369

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011612A MX354127B (es) 2012-03-27 2013-03-07 Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central.

Country Status (9)

Country Link
US (3) US9464050B2 (es)
EP (1) EP2831043B1 (es)
AU (1) AU2013240486B2 (es)
CA (1) CA2868459A1 (es)
ES (1) ES2924829T3 (es)
HK (1) HK1205503A1 (es)
MX (1) MX354127B (es)
NZ (1) NZ630612A (es)
WO (1) WO2013148103A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2608520C2 (ru) * 2009-10-19 2017-01-19 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
WO2015095963A1 (en) 2013-12-23 2015-07-02 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
ES2771849T3 (es) * 2014-02-12 2020-07-07 Amicus Therapeutics Inc Derivados de azúcares que comprenden restos que contienen azufre, métodos para prepararlos y métodos para emplearlos en el tratamiento de MPS IIIC
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
CN110325516A (zh) 2016-12-29 2019-10-11 米尼奥尔克斯治疗有限公司 杂芳基化合物和它们的用途
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
HK1001832A1 (en) 1991-04-25 1998-07-10 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
DE69332105T2 (de) 1992-09-29 2003-03-06 Inhale Therapeutic Systems, San Carlos Pulmonale abgabe von aktiven fragmenten des parathormons
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6794694B2 (en) 2000-12-21 2004-09-21 Agere Systems Inc. Inter-wiring-layer capacitors
JP4060572B2 (ja) 2001-11-06 2008-03-12 株式会社東芝 半導体記憶装置及びその製造方法
KR100446293B1 (ko) 2002-01-07 2004-09-01 삼성전자주식회사 저항체를 포함하는 반도체 소자 제조 방법
JP2003273230A (ja) 2002-03-19 2003-09-26 Nec Electronics Corp 半導体装置及びその製造方法
US6720232B1 (en) 2003-04-10 2004-04-13 Taiwan Semiconductor Manufacturing Company Method of fabricating an embedded DRAM for metal-insulator-metal (MIM) capacitor structure
BRPI0416216A (pt) * 2003-11-12 2006-12-26 Amicus Therapeutics Inc composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
US7425740B2 (en) 2005-10-07 2008-09-16 Taiwan Semiconductor Manufacturing Company, Ltd. Method and structure for a 1T-RAM bit cell and macro
JP2007201101A (ja) 2006-01-25 2007-08-09 Nec Electronics Corp 集積回路装置および回路製造方法
DK1860101T3 (da) 2006-05-24 2011-07-25 Amicus Therapeutics Inc Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
WO2010048532A1 (en) 2008-10-24 2010-04-29 Amicus Therapeutics, Inc. Multiple compartment dosing model
US9044437B2 (en) * 2009-10-19 2015-06-02 Amicus Therapeutics, Inc. Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
KR101880411B1 (ko) * 2009-10-19 2018-07-19 아미쿠스 세라퓨틱스, 인코포레이티드 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물
RU2608520C2 (ru) 2009-10-19 2017-01-19 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
JP2012064627A (ja) 2010-09-14 2012-03-29 Elpida Memory Inc 半導体装置の製造方法
JP5689392B2 (ja) 2011-09-02 2015-03-25 ルネサスエレクトロニクス株式会社 半導体装置及び半導体装置の製造方法
KR102023720B1 (ko) 2012-09-03 2019-09-20 엘지이노텍 주식회사 보이스 코일 모터

Also Published As

Publication number Publication date
US20150050263A1 (en) 2015-02-19
NZ630612A (en) 2016-11-25
US20170365609A1 (en) 2017-12-21
AU2013240486B2 (en) 2017-10-26
US10224333B2 (en) 2019-03-05
HK1205503A1 (en) 2015-12-18
AU2013240486A1 (en) 2014-09-25
MX2014011612A (es) 2014-10-17
WO2013148103A1 (en) 2013-10-03
ES2924829T3 (es) 2022-10-11
EP2831043B1 (en) 2022-07-27
US9750733B2 (en) 2017-09-05
EP2831043A1 (en) 2015-02-04
US20170020853A1 (en) 2017-01-26
CA2868459A1 (en) 2013-10-03
US9464050B2 (en) 2016-10-11

Similar Documents

Publication Publication Date Title
WO2015031564A3 (en) Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors
CL2013000714A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras.
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
EA201590748A1 (ru) Противовирусные соединения против rsv
WO2015011284A3 (en) Inhibitors of fapp2 and uses thereof
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
NZ710111A (en) Quinoline and quinoxaline amides as modulators of sodium channels
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
NZ710270A (en) Pyridone amides as modulators of sodium channels
MY199894A (en) Prmt5 inhibitors and uses thereof
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2015001599A1 (es) Compuestos derivados de (piridin o pirimidin)-(piperidina o piperazina) sustituidos o sus sales, inhibidores de la colesterol 24-hidroxilasa (ch24h); medicamento; metodo de inhibicion de la ch24h; metodo para prevenir o tratar; y uso para la prevencion o tratamiento de epilepsia, alzheimer y parkinson, entre otras enfermedades.
CL2008002271A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida o su sal farmaceutica; proceso de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar un trastorno del sistema nervioso central tal como alzheimer, demencia senil, parkinson.
IN2014KN02601A (es)
MX342329B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MX354127B (es) Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central.
MD20150071A2 (ro) Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
NZ709985A (en) Nitroxyl donors with improved therapeutic index

Legal Events

Date Code Title Description
FG Grant or registration